Common Contracts
14 similar Underwriting Agreement contracts by Synergy CHC Corp., Ani Pharmaceuticals Inc, Iaso Pharma Inc, others
1,898,735 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • May 12th, 2023 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,898,735 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 284,810 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
Synergy CHC Corp. [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 5th, 2022 • Synergy CHC Corp. • Medicinal chemicals & botanical products • New York
The undersigned understands that you, as representative (the “Representative”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule A to such agreement (collectively, the “Underwriters”), with Synergy CHC Corp, a Nevada corporation (the “Company”), providing for a public offering (the “Offering”) of shares (the “Shares”) of common stock of the Company (the “Common Stock”) pursuant to a Registration Statement on Form S-1 filed or to be filed with the Securities and Exchange Commission (the “SEC”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.
1,500,000 Shares of Common Stock ANI PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 4th, 2021 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,500,000 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 225,000 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
Synergy CHC Corp. [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 22nd, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • New York
The undersigned understands that you, as representative (the “Representative”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule A to such agreement (collectively, the “Underwriters”), with Synergy CHC Corp, a Nevada corporation (the “Company”), providing for a public offering (the “Offering”) of shares (the “Shares”) of common stock of the Company (the “Common Stock”) pursuant to a Registration Statement on Form S-1 filed or to be filed with the Securities and Exchange Commission (the “SEC”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.
Synergy CHC Corp. [●] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 20th, 2021 • Synergy CHC Corp. • Medicinal chemicals & botanical products • New York
The undersigned understands that you, as representative (the “Representative”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule A to such agreement (collectively, the “Underwriters”), with Synergy CHC Corp, a Nevada corporation (the “Company”), providing for a public offering (the “Offering”) of shares (the “Shares”) of common stock of the Company (the “Common Stock”) pursuant to a Registration Statement on Form S-1 filed or to be filed with the Securities and Exchange Commission (the “SEC”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.
● ] Shares Five Star Bancorp Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2021 • Five Star Bancorp • State commercial banks • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • April 17th, 2020 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations • New York
Arcturus Therapeutics Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 4,117,650 shares of its common stock, par value $0.001 per share (the “Common Stock”). The 4,117,650 shares of Common Stock to be sold by the Company are called the “Firm Shares.” The Company also proposes to issue and sell to the several Underwriters up to an additional 617,647 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated
27,500,000 Shares of Common Stock EXICURE, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2019 • Exicure, Inc. • Pharmaceutical preparations • New York
Exicure, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 27,500,000 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 4,125,000 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
4,000,000 Shares IASO PHARMA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2011 • Iaso Pharma Inc • Pharmaceutical preparations • New York
IASO PHARMA, INC, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters (as defined below) an aggregate of 4,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”) pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”).
4,000,000 Shares IASO PHARMA, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 27th, 2011 • Iaso Pharma Inc • Pharmaceutical preparations • New York
IASO PHARMA, INC, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters (as defined below) an aggregate of 4,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”) pursuant to and in accordance with the terms and conditions of this underwriting agreement (the “Agreement”).
UNDERWRITING AGREEMENTUnderwriting Agreement • December 17th, 2010 • Longhai Steel Inc. • Steel works, blast furnaces & rolling & finishing mills • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • December 2nd, 2010 • Longhai Steel Inc. • Steel works, blast furnaces & rolling & finishing mills • New York
2,000,000 SHARES OF COMMON STOCK BUDDHA STEEL INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 22nd, 2010 • Buddha Steel, Inc. • Steel works, blast furnaces & rolling & finishing mills • New York
American Depository Shares CHINA HYDROELECTRIC CORPORATION UNDERWRITING AGREEMENT August [ ], 2009Underwriting Agreement • December 8th, 2009 • China Hydroelectric Corp • New York
